INTRODUCTION {#s1}
============

Intrahepatic cholangiocarcinoma (ICC) accounts for 10%-20% of primary hepatic malignancy, with its increasing global incidence only second to hepatocellular carcinoma (HCC) \[[@R1]--[@R4]\]. Most patients with unresectable ICC died within 6-12 months after disease diagnosis \[[@R5], [@R6]\], and liver resection is the only established therapy currently to achieve long-term survival in selected patients \[[@R7], [@R8]\]. Unfortunately, only about 20%-40% of patients with ICC are suitable for surgical resection and the overall surgical prognosis remains unsatisfactory \[[@R7]\]. The 5-year tumor recurrence rate has been reported to be 53%-79% and the corresponding survival rate 23.0%-35.2% \[[@R7], [@R9]--[@R17]\]. To date, the report on long-term survival after liver resection for ICC remains scarce, especially that based on follow-up of longer than 10 years. We only found one study that reported a 10-year survival of 23.1% in ICC patients after hepatic resection through the Kaplan--Meier survival analysis \[[@R18]\], which as we think might have overestimated the actual survival status for the biased censoring process associated with the Kaplan--Meier approach itself \[[@R19]--[@R21]\]. To the best of our knowledge, the actual 10-year follow-up and survival data in these patients have not been reported.

Of note, the risk factors associated with the prognosis in ICC patients after curative hepatectomy remain controversial \[[@R10]--[@R12], [@R15], [@R17], [@R18]\]. In particular, factors demonstrated as significant in some studies were found by others to be not significant. An example of this is tumor diameter, a few studies deemed it to be a non-significant factor associated with prognosis \[[@R11], [@R15], [@R17]\], but others have demonstrated its negative impact on survival in multivariate analysis \[[@R10], [@R12], [@R18]\]. It is thus difficult to accurately assess the true prognostic factors. Therefore, further studies with longer-term follow-up are required to better identify the survival factors and it is important to evaluate the characteristics of ICC patients who survived long-term after curative liver resection.

The aim of this study was to investigate the 10-year actual survival rates after initial hepatic resection in ICC patients, identify the characteristics of patients that have survived more than 10 years and discover the prognostic factors associated with long-term survival using competing risk survival analysis.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

Baseline clinicopathologic characteristics of all 251 patients are shown in Table [1](#T1){ref-type="table"}. The median age of patients was 53 years (interquartile range \[IQR\], 46--62 years) and 160 (63.7%) patients are male. Among all patients, 23 (9.2%) patients had hepatolithiasis, 122 (48.6%) patients had positive hepatitis B surface antigen (HBsAg), 5 (2.0%) patients had positive anti-HCV, 49 (19.5%) patients had cirrhosis, and 171 (68.1%) patients had solitary tumor. The median tumor size was 5.4 cm (IQR, 4.0--8.0 cm). Seventy-seven (30.7%) patients underwent major liver resection, and nodal metastasis was found in 43 (17.1%) patients.

###### Clinicopathologic characteristics (n = 251)

  Variable                          Number (%) / median (IQR)
  --------------------------------- ---------------------------
  **Age**, year                     53.0 (46.0 -- 62.0)
  **Gender**                        
   Male                             160 (63.7)
   Female                           91 (36.3)
  **Hepatolithiasis**               
   Yes                              23 (9.2)
   No                               228 (90.8)
  **HBsAg**                         
   Positive                         122 (48.6)
   Negative                         129 (51.4)
  **HBeAg**                         
   Positive                         19 (7.6)
   Negative                         232 (92.4)
  **Anti-HCV**                      
   Positive                         5 (2.0)
   Negative                         246 (98.0)
  **AFP**, μg/L                     4.2 (2.4 -- 15.3)
  **CEA**, μg/L                     2.1 (1.3 -- 4.3)
  **CA 19--9**, U/L                 37.5 (13.7 -- 196.9)
  **TBIL**, μmol/L                  13.5 (10.7 -- 18.3)
  **ALB**, g/L                      42.6 (39.9 -- 45.2)
  **ALT**, U/L                      31.3 (19.1 -- 51.0)
  **AST**, U/L                      29.6 (23.2 -- 43.7)
  **ALP**, U/L                      106.0 (80.0 -- 147.0)
  **PLT**, 10^9^/L                  170.0 (133.0 -- 219.0)
  **PT**, seconds                   11.9 (11.3 -- 12.8)
  **Child-Pugh grade**              
   A                                237 (94.4)
   B                                14 (5.6)
  **Cirrhosis**                     
   Yes                              49 (19.5)
   No                               202 (80.5)
  **Tumor diameter**, cm            5.4 (4.0 -- 8.0)
  **Tumor number**                  
   Multiple                         80 (31.9)
   Solitary                         171 (68.1)
  **Vascular invasion**             
   Presence                         33 (13.1)
   Absence                          218 (86.9)
  **Nodal metastasis**\*            
   Yes                              43 (17.1)
   No                               208 (82.9)
  **Local extrahepatic invasion**   
   Yes                              22 (8.8)
   No                               229 (91.2)
  **Surgical margin**, cm           
   \> 1                             64 (25.5)
   ≤ 1                              187 (74.5)
  **Tumor differentiation**         
   Well                             11 (4.4)
   Moderate                         208 (82.9)
   Poor                             32 (12.7)
  **Perineural invasion**           
   Yes                              7 (2.8)
   No                               244 (97.2)
  **Macroscopic type**              
   MF                               238 (94.8)
   Non-MF                           13 (5.2)
  **Major hepatectomy**             
   Yes                              77 (30.7)
   No                               174 (69.2)
  **Operative blood loss**, ml      300.0 (150.0 -- 500.0)
  **Blood transfusion**             
   Yes                              39 (15.5)
   No                               212 (84.5)
  **Surgical complication**         
   Yes                              72 (28.7)
   No                               179 (71.3)
  **Grade of complication**         
   I/II                             46 (63.9)
   III/IV                           26 (36.1)

Abbreviations: HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HCV, hepatitis C virus; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbonhydrateantigen19-9; TBIL, total bilirubin; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; PLT, platelet; PT, prothrombin time; MF, mass-forming; IQR, interquartile range.

\*: nodes that were evaluated as normal and did not undergo dissection were defined as no metastasis in 98 patients.

Tumor recurrence and overall survival {#s2_2}
-------------------------------------

The median follow-up period was 32.1 months (IQR, 18.0--81.2 months). During the follow-up period, 220 (87.6%) patients developed tumor recurrence, and 165 of these patients developed recurrence within five years, 51 patients between five and ten years, and 4 patients beyond ten years after surgery. For the 238 patients (94.8%) who died during the study period, 170 patients died within five years, 60 patients between five and ten years, and 8 patients after ten years postoperatively. The remaining 13 patients (5.2%) were alive at the time of censor. Consequently, of all the 251 patients, 230 (91.6%) patients survived for less than, and 21 patients for more than 10 years after surgery.

Among the 13 survivors, 7 patients survived with tumor recurrence, and the remaining 6 patients were alive and free of recurrence. Among the 238 patients who died, 209 patients died of relapse, and another 4 patients who had recurrence but died of other reasons (hepatic failure, upper gastrointestinal bleeding, other malignant diseases and renal failure). The remaining 25 patients who did not have recurrence died of hepatic failures (n = 3), upper gastrointestinal bleeding (n = 1), other malignant diseases (n = 2), cardiovascular diseases (n = 4), respiratory diseases (n = 2), renal failure (n = 1), diabetic complication (n = 1), suicide (n = 1) and miscellaneous reasons (n = 10). Deaths that were caused by ICC recurrence or by other reasons were classified as ICC-related and non-ICC-related deaths, respectively. In this study, there were 209 ICC-related and 29 non-ICC-related deaths.

The median time to recurrence (TTR) was 13.5 months (95% confidence interval \[CI\], 8.3--18.7 months) and the 5-, 7-, and 10-year tumor recurrence rates were 70.3%, 83.1% and 93.5%, respectively (Figure [1A](#F1){ref-type="fig"}). The median survival was 21.7 months (95% CI, 16.3--21.2 months) and the 5-, 7-, and 10-year overall survival (OS) rates were 32.3%, 22.3% and 8.4%, respectively (Figure [1B](#F1){ref-type="fig"}).

![Recurrence, OS, cumulative incidence of ICC-related death and recurrence after curative hepatectomy\
**(A)** Recurrence; **(B)** OS; **(C)** Cumulative incidence of ICC-related death; **(D)** Cumulative incidence of recurrence.](oncotarget-08-44521-g001){#F1}

Factors associated with ICC-related death {#s2_3}
-----------------------------------------

During the analysis, non-ICC-related deaths were considered as competing events for ICC-related deaths, and the 5-, 7- and 10-year cumulative incidences of ICC-related deaths were 58.6%, 68.2% and 80.9%, respectively (Figure [1C](#F1){ref-type="fig"}). The results of the univariate analysis on ICC-related deaths are shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Multivariate analysis demonstrated that carcinoembryonic antigen (CEA) \> 10 U/mL (hazard ratio \[HR\]: 1.812; 95% confidence interval \[CI\]: 1.180--2.784), carbohydrate antigen 19-9 (CA19-9) \> 39 U/mL (1.711; 1.261--2.322), tumor diameter \> 5 cm (1.369; 1.011--1.853), multiple tumors (1.614; 1.183--2.203), vascular invasion (1.847; 1.246--2.739), nodal metastasis (2.302; 1.552--3.413) and local extrahepatic invasion (2.284; 1.349--3.869) were significantly associated with ICC-related deaths (Table [2](#T2){ref-type="table"}).

###### Factors associated with cause-specific hazard of recurrence and ICC-related death according to multivariate Cox\'s Proportional Hazards Model

  Variable                                     Tumor recurrence         Survival                            
  -------------------------------------------- ------------------------ ---------- ------------------------ ---------
  **CEA**, μg/L, \> 10 vs. ≤ 10                1.794 (1.166 -- 2.761)   0.008      1.812 (1.180 -- 2.784)   0.007
  **CA 19--9**, U/L, \> 39 vs. ≤ 39            1.641 (1.218 -- 2.213)   0.001      1.711 (1.261 -- 2.322)   0.001
  **Tumor diameter**, cm, \> 5 vs. ≤ 5         1.445 (1.080 -- 1.933)   0.013      1.369 (1.011 -- 1.853)   0.042
  **Tumor number**, Multiple vs. Solitary      1.464 (1.089 -- 1.968)   0.011      1.614 (1.183 -- 2.203)   0.003
  **Vascular invasion**, Yes vs. No            1.944 (1.317 -- 2.868)   0.001      1.847 (1.246 -- 2.739)   0.002
  **Nodal metastasis**, Yes vs. No             2.034 (1.376 -- 3.008)   \<0.001    2.302 (1.552 -- 3.413)   \<0.001
  **Local extrahepatic invasion**,Yes vs. No   1.933 (1.159 -- 3.223)   0.012      2.284 (1.349 -- 3.869)   0.002

Abbreviations: CEA, carcinoembryonic antigen; CA19-9, carbonhydrate antigen 19-9; HR, hazard ratio; CI, confidence interval.

Factors associated with recurrence {#s2_4}
----------------------------------

Death before ICC recurrence was considered as a competing event for recurrence, and the 5-, 7- and 10-year cumulative incidences of ICC recurrence were 65.7%, 76.9% and 85.7%, respectively (Figure [1D](#F1){ref-type="fig"}). The results of the univariate analysis on ICC recurrence are shown in the [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Multivariate analysis identified that CEA \> 10 U/mL (HR: 1.794; 95% CI: 1.166--2.761), CA19-9 \> 39 U/mL (1.641; 1.218--2.213), tumor diameter \> 5 cm (1.445; 1.080--1.933), multiple tumors (1.464; 1.089--1.968), vascular invasion (1.944; 1.317--2.868), nodal metastasis (2.034; 1.376--3.008) and local extrahepatic invasion (1.933; 1.159--3.223) were associated with recurrence (Table [2](#T2){ref-type="table"}).

Comparison of clinicopathologic data between patients who survived ≥ and \< 10 years {#s2_5}
------------------------------------------------------------------------------------

Comparison of the clinicopathologic data between patients who survived ≥ and \< 10 years is shownin Table [3](#T3){ref-type="table"}. Whencompared with patients who survived \< 10 years, patientswhosurvived ≥ 10 years had significantly lower levels of CEA (*p* = 0.018), CA19-9 (p = 0.020), and alkaline phosphatase (ALP, *p* = 0.002), smaller tumor size (p \< 0.001), less operative blood loss (*p* = 0.001), and a lower incidence of multiple nodules (*p* = 0.040). No patient who survived ≥ 10 years had nodal metastasis and local extrahepatic invasion.

###### Clinicopathologic characteristics between patients survived \< or ≥ 10 years

  Variable                          Number (%) / median (IQR)   *p* value                
  --------------------------------- --------------------------- ------------------------ ----------
  **Age**, year                     53.0 (46.0 -- 61.0)         56.0 (42.0 -- 637.0)     0.608
  **Gender**                                                                             
   Male                             146 (63.5)                  14 (66.7)                0.771
   Female                           84 (36.5)                   7 (33.3)                 
  **Hepatolithiasis**                                                                    
   Yes                              22 (9.6)                    1 (4.8)                  0.737
   No                               208 (90.4)                  20 (95.2)                
  **HBsAg**                                                                              
   Positive                         109 (47.4)                  13 (61.9)                0.203
   Negative                         121 (52.6)                  8 (38.1)                 
  **HBeAg**                                                                              
   Positive                         17 (7.4)                    2 (9.5)                  1.000
   Negative                         213 (92.6)                  19 (90.5)                
  **Anti-HCV**                                                                           
   Positive                         3 (1.3)                     2 (9.5)                  0.078
   Negative                         227 (98.7)                  19 (90.5)                
  **AFP**, μg/L                     4.2 (2.4 -- 15.5)           6.2 (2.3 -- 12.7)        0.725
  **CEA**, μg/L                     2.3 (1.3 -- 4.4)            1.7 (0.8 -- 2.5)         0.018
  **CA 19--9**, U/L                 40.6 (13.9 -- 246.1)        22.1 (9.0 -- 35.5)       0.020
  **TBIL**, μmol/L                  13.5 (10.7 -- 18.4)         12.1 (10.4 -- 15.7)      0.273
  **ALB**, g/L                      42.6 (39.8 -- 45.1)         44.6 (41.0 -- 46.5)      0.055
  **ALT**, U/L                      31.2 (19.2 -- 49.9)         31.8 (18.6 -- 57.3)      0.800
  **AST**, U/L                      29.6 (23.4 -- 46.2)         31.9 (20.3 -- 41.0)      0.569
  **ALP**, U/L                      108.0 (82.0 -- 151.3)       84.0 (68.0 -- 101.5)     0.002
  **PLT**, 10^9^/L                  168.5 (133.0 -- 219.0)      171.0 (141.0 -- 196.5)   0.995
  **PT**, seconds                   11.9 (11.3 -- 12.8)         12.1 (11.6 -- 13.1)      0.333
  **Child-Pugh grade**                                                                   
   A                                216 (93.9)                  21 (100.0)               0.284
   B                                14 (6.1)                    0 (0.0)                  
  **Cirrhosis**                                                                          
   Yes                              45 (19.6)                   4 (19.0)                 1.000
   No                               185 (80.4)                  17 (81.0)                
  **Tumor diameter**, cm            5.5(4.2 -- 8.0)             3.8 (2.4 -- 5.0)         \< 0.001
  **Tumor number**                                                                       
   Multiple                         78 (33.9)                   2 (9.5)                  0.040
   Solitary                         152 (66.1)                  19 (90.5)                
  **Vascular invasion**                                                                  
   Presence                         32 (13.9)                   1 (4.8)                  0.395
   Absence                          198 (86.1)                  20 (95.2)                
  **Nodal metastasis**                                                                   
   Yes                              43 (18.7)                   0 (0.0)                  0.030
   No                               187 (81.3)                  21 (100.0)               
  **Local extrahepatic invasion**                                                        
   Yes                              22 (9.6)                    0 (0.0)                  0.231
   No                               208 (90.4)                  22 (100.0)               
  **Surgical margin**, cm                                                                
   \> 1                             57 (24.8)                   7 (33.3)                 0.389
   ≤ 1                              173 (75.2)                  14 (66.7)                
  **Tumor differentiation**                                                              
   Well                             9 (3.9)                     2 (9.5)                  0.540
   Moderate                         192 (83.5)                  16 (76.2)                
   Poor                             29 (12.6)                   3 (14.3)                 
  **Perineural invasion**                                                                
   Yes                              7 (3.0)                     0 (0.0)                  1.000
   No                               223 (97.0)                  21 (100.0)               
  **Macroscopic type**                                                                   
   MF                               217 (94.3)                  21 (100.0)               0.609
   Non-MF                           13 (5.7)                    0 (0.0)                  
  **Major hepatectomy**                                                                  
   Yes                              72 (31.3)                   5 (23.8)                 0.476
   No                               158 (68.7)                  16 (76.2)                
  **Operative blood loss**, ml      300.0 (200.0 -- 500.0)      150.0 (100.0 -- 350.0)   0.011
  **Blood transfusion**                                                                  
   Yes                              38 (16.5)                   1 (4.8)                  0.267
   No                               192 (83.5)                  20 (95.2)                
  **Surgical complication**                                                              
   Yes                              67 (29.1)                   5 (23.8)                 0.606
   No                               163 (70.9)                  16 (76.2)                
  **Grade of complication**                                                              
   I/II                             43 (64.2)                   3 (60.0)                 1.000
   III/IV                           24 (35.8)                   2 (40.0)                 

Abbreviations: HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HCV, hepatitis C virus; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbonhydrateantigen19-9; TBIL, total bilirubin; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; PLT, platelet; PT, prothrombin time; MF, mass-forming; HR, hazard ratio; CI, confidence interval.

In addition, comparison of the clinicopathologic characteristics of the patients who survived 5-10 years and those who survived ≥ 10 years revealed that the latter group of patients had significantly smaller tumor size (p = 0.049). There were no significant differences in the other baseline characteristics ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}).

Treatment for recurrence between patients who survived ≥ and \< 10 years {#s2_6}
------------------------------------------------------------------------

For patients who survived \< 10 years, 206 patients had recurrences, in which 114 patients developed recurrences within 1 year, 49 patients between 2 and 5 years, and only 43 patients developed recurrences between 5 and 10 years postoperatively. Among all these patients who developed recurrences, 127 (61.6%) patients had intrahepatic recurrence only, 36 (17.5%) patients had extrahepatic metastases only, and 43 (20.9%) patients had intra- and extrahepatic recurrent diseases. The treatment for patients with recurrences consisted of re-hepatectomy (n = 14), percutaneous radiofrequency ablation (PRFA, n = 28), transarterial chemoembolization (TACE, n = 35), chemotherapy (n = 47), and conservative therapy (n = 82).

Among the patients who survived ≥ 10 years, 14 patients had recurrences during follow-up, in which 2 patients developed recurrences within 5 years, 8 patients between 5 and 10 years, and the remaining 4 patients beyond 10 years postoperatively. Among these 14 patients, 12 (85.8%) patients had intrahepatic recurrence only, 1 (7.1%) patient had extrahepatic metastases only, and 1 (7.1%) patient had intra- and extrahepatic recurrent diseases. The treatment for recurrences consisted of re-hepatectomy (n = 6), PRFA (n = 4), TACE (n = 2), chemotherapy (n = 1), and conservative therapy (n = 1). Among the 21 patients who survived ≥ 10 years, 8 patients died of ICC recurrence (n = 7) or cardiovascular diseases (n = 1) beyond ten years after surgery. Seven and 6 of the remaining 13 patients survived with and without tumor recurrence respectively, on the date when this study was censored.

Clinicopathologic features of the 10-year recurrence-free survivors {#s2_7}
-------------------------------------------------------------------

Table [4](#T4){ref-type="table"} shows the clinicopathologic features of the 10-year recurrence-free survivors (cases 1--7). Of these 7 patients, 6 (case 2--7) patients were still alive on the date when the study was censored and 1 (case 1) patient died of cardiovascular disease. Six (case 1--6) patients were males. All the 7 survivors had Child-Pugh grade A liver function and they had no cirrhosis. Four of these 7 patients were HBsAg positive. Histopathological examination showed that all the 7 patients had a solitary moderately differentiated tumor with a diameter which ranged from 2.0 to 5.0 cm. There were no evidences of nodal metastasis or local extrahepatic invasion in these 7 patients.

###### Clinicopathological data of 10-year recurrence-free survivors

  Case   Age(years)   Sex   HBsAg      Cirrhosis   Child-Puge   Tumor diameter (cm)   Tumor number   Differentiation   Nodal metastasis   VI\*   OS(monthes)   Outcome
  ------ ------------ ----- ---------- ----------- ------------ --------------------- -------------- ----------------- ------------------ ------ ------------- ---------
  1      58           M     Positive   No          A            2.0                   Solitary       Moderate          No                 No     150.6         Dead
  2      68           M     Positive   No          A            2.2                   Solitary       Moderate          No                 Yes    122.9         Alive
  3      60           M     Positive   No          A            2.5                   Solitary       Moderate          No                 No     160.8         Alive
  4      41           M     Negative   No          A            3.0                   Solitary       Moderate          No                 No     121.5         Alive
  5      50           M     Negative   No          A            4.0                   Solitary       Moderate          No                 No     139.6         Alive
  6      59           M     Negative   No          A            5.0                   Solitary       Moderate          No                 No     123.3         Alive
  7      56           F     Positive   No          A            2.5                   Solitary       Moderate          No                 No     127.1         Alive

Abbreviation: ICC, intrahepatic cholangiocarcinoma; VI, vascular invasion; OS, overall survival; M, male; F, female.

\*: vascular invasion in this patient is microscopic vascular invasion.

DISCUSSION {#s3}
==========

Liver resection has been the only curative therapy in selected patients with ICC \[[@R7], [@R8]\]. So far, no published study with enough follow-up time is available to provide robust actual 10-year outcomes in ICC patients following curative resection. To the best of our knowledge, the present study has provided an actual 10-year OS of 8.4% in ICC patients after curative resection through actual follow-up.

A recent study by Spolverato G *et al* reported a cure model to define a statistical cure for ICC and estimated the probability of being cured after liver resection, which indicated that a statistical cure was possible in some surgically treated patients with ICC \[[@R22]\]. However, the model can be considered useful mathematically only when it is believed that a cure fraction exists \[[@R23], [@R24]\]. In our study, a proportion of ICC patients did experience a plateauing of survival after a certain period of time, which echoed the results from Spolverato G *et al* and also indicated that cure was indeed possible in selected ICC patients after hepatectomy.

The Kaplan-Meier analysis frequently used to measure outcome risks over time provides a nonparametric estimate of the overall survival probability of an event of interest. However, the process of censoring associated with this method might lead to a bias and a gross overestimation of survival \[[@R19]--[@R21]\]. In addition, ignoring competing events in the statistical analysis can easily lead to flawed results and conclusions \[[@R22]\]. Therefore, cumulative incidences of recurrence and ICC-related death were used in the present study to measure outcome risks after a long-term follow up \[[@R25], [@R26]\]. We found that the 10-year cumulative incidence of recurrence was notably 80.2% and the cumulative ICC-related mortality was 80.9% at 10 years. In this study, although most tumor recurrences developed within 5 years after surgery, some patients still developed recurrences thereafter. Surprisingly, recurrence of ICC may occur even after a 10-year recurrence-free period: four patients who survived ≥ 10 years in our study developed recurrence beyond 10 years after curative surgery. Whether the delayed recurrence in long-term survivors was likely to be the result from *de novo* ICC or the progression of occult metastatic diseases still warrants validation by future studies \[[@R27], [@R28]\]. Nevertheless, this study has indicated that tumor recurrence was a persistent problem and the leading cause of death for ICC patients after surgery. Although how long a follow-up period after surgery should be remains to be determined, our data supported the importance of a very long-term follow-up, even lifetime, for ICC patients after liver resection.

In the present study, the predictive analysis of variables associated with prognosis was conducted using the competing risks model. The results showed that CEA \> 10 U/mL, CA19-9 \> 39 U/mL, tumor diameter \> 5 cm, multiple tumors, vascular invasion, nodal metastasis and local extrahepatic invasion were closely associated with recurrence and ICC-related death. The result was consistent with the outcomes reported from other studies \[[@R9]--[@R14]\]. In addition, our data also demonstrated that tumor diameter \> 5 cm was an independent risk factor associated with prognosis, despite the conflicting results from the previous studies with regard to the association between tumor diameter and prognosis after curative surgery for ICC \[[@R10]--[@R12], [@R15], [@R17], [@R18]\]. One explanation could be that previous studies did not specifically consider the confounding of competing events and did not have long-term postoperative follow-up.

This study specifically investigated the patients with ICC who have survived more than 10 years after surgery, and found that these patients experienced recurrence later and were more likely to have smaller and solitary tumor without any nodal metastasis or local extrahepatic invasion, as well as lower CEA, CA19-9 and ALP levels and less operative blood loss. Although the distribution of the clinicopathologic factors in this study reflected the heterogeneity of the population, it indicated that the presence of the factors mentioned above could preclude long-term survival after curative surgery and these patients clearly deserve rigorous and regular follow-up.

Our study had some limitations. First, given its retrospective nature, this study is inevitably exposed to selection bias. Second, the 10-year survivors were relatively small in number for a more robust statistical analysis. Therefore, further studies on a larger number of patients are necessary to evaluate the prognostic factors of ICC more accurately.

In conclusion, 10-year survival after liver resection for ICC is possible and can be expected in approximately 8.4% of patients. Recurrence of ICC might occur even after a 10-year recurrence-free period. Tumor diameter was a risk factor of long-term prognoses. In addition, long-term or even life-long follow-up after resection of ICC is crucial.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

A total of 313 consecutive patients who underwent partial hepatectomy for pathologically proven ICC between April 2003 and August 2006 at the Department of Hepatic Surgery of the Eastern Hepatobiliary Surgery Hospital (EHBH) were enrolled into the study. Patients met the following criteria: (1) no previous history of other malignancies; (2) had not received any anti-cancer therapy before surgery; (3) underwent a R0 resection, defined as complete removal of macroscopic nodules and absence of microscopic disease at the surgical margin \[[@R9]\]; (4) had not died within 30 days from the date of surgery, and (5) had complete clinical data and follow-up information. Finally, 251 patients were included for further analysis.

This study was approved by the Institutional Ethics Committee of the EHBH. Informed consent was obtained from all the patients before surgery for their data to be used for research.

Preoperative examination and surgical procedure {#s4_2}
-----------------------------------------------

After a detailed history and a complete physical examination, all patients were tested for liver and renal functions, hepatitis B and C serology, CA19-9, CEA, α-fetoprotein, abdominal ultrasound, chest x-ray, contrast-enhanced magnetic resonance imaging (MRI) and/or computed tomography (CT) scan of the abdomen. A preoperative diagnosis of ICC was mainly based on the combination of the serological and radiological findings \[[@R15]\], and on the clinical manifestations which were different from HCC and other metastatic malignancies. The lymph node status was evaluated with contrast-enhanced CT scans or MRI.

Partial hepatectomies were performed on patients with good general condition and liver functional reserve, technically resectable tumor and sufficient estimated volume of future liver remnant, and without any evidences of distant tumor metastases \[[@R10]\]. Perihepatic lymph node adenopathy on preoperative CT scan or MRI was considered primarily for operation as long as the nodes could be completely and safely resected, which was judged by experienced surgeons. Liver resection of three or more segments was defined as major resection. Any additional nodules, which were found intraoperatively, were also resected if the surgeon considered the resection to be safe. Local extrahepatic invasions, defined as direct invasion of any adjacent organs and structures, which included the colon, duodenum, stomach, common bile duct, retrohepatic vena cava, abdominal wall and diaphragm, were also resected if the surgeon considered the resection to be safe. Dissection of perihepatic lymph nodes was only carried out in patients who were preoperatively or intraoperatively diagnosed as ICC based on imaging, serology and frozen section results. Histopathological study of the resected specimens was performed independently by three pathologists and disagreements were resolved through discussion until a consensus was reached \[[@R29]\]. Perioperative complications were observed and defined as grade I-IV based on the previously reported classification system \[[@R30]\].

Follow-up and endpoints {#s4_3}
-----------------------

Patients were followed-up once every 2 months in the first 2 years after surgery and once every 3 months thereafter. At each follow-up visit, serum CEA and CA19-9 levels, liver function test, and abdominal ultrasound were performed routinely. Contrast-enhanced CT or MRI was performed once every 3-6 months or earlier if tumor recurrence or metastasis was suspected. Bone metastases were detected by scintigraphy or positron emission tomography (PET). ICC recurrence was diagnosed based on the combined findings of the above examinations. Deaths were classified as "ICC-related death" and "non-ICC-related death" which were caused by other reasons, including hepatic failures, upper gastrointestinal bleeding, other malignant diseases, cardiovascular diseases, renal failure, diabetic complication, or other causes.

OS and TTR were used as end points. OS was defined as the interval between the date of surgery and the date of patient death or last follow-up. TTR was the interval between the date of surgery and the date when recurrence/metastasis was diagnosed. This study was censored on October 25, 2016.

Statistical analysis {#s4_4}
--------------------

Continuous variables were initially explored for normal distribution using the Shapiro-Wilk test. As a normal distribution could not be confirmed for most variables, the variables were expressed as median and IQR. Differences between the groups were compared by the *t*-test or Mann-Whitney *U* test. Categorical variables were compared using the χ^2^ test, Yates' correction test or Fisher\'s exact test. The collinearity was assessed by examining the variance inflation factors, and no collinearity was found between the variables. Survival curves were estimated by the Kaplan--Meier method.

Cumulative incidences of recurrence and ICC-related death were estimated while taking into account the competing risk of non-ICC-related death using a competing risk analysis as defined by Fine and Gray \[[@R31]\]. Predictive analysis of variables associated with the cause-specific hazard of recurrence and ICC-related death was done using the univariate and multivariate Cox proportional hazard model \[[@R31]\].

All statistical analyses were performed using SPSS 19.0 for Windows (SPSS, Chicago, IL) and R software v. 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria; [www.r-project.org](http://www.r-project.org)). All reported *p* values were two-sided, and *p* \< 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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ICC

:   intrahepatic cholangiocarcinoma

CEA

:   carcinoembryonic antigen

CA19-9

:   carbohydrate antigen 19-9

HCC

:   hepatocellular carcinoma

IQR

:   interquartile range

HBsAg

:   hepatitis B surface antigen

HCV

:   hepatitis C virus

TTR

:   time to recurrence

CI

:   confidence interval

OS

:   overall survival

HR

:   hazard ratio

ALP

:   alkaline phosphatase

PRFA

:   percutaneous radiofrequency ablation

TACE

:   transarterial chemoembolization

MRI

:   magnetic resonance imaging

CT

:   computed tomography

PET

:   positron emission tomography
